Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans – Pulmonary Fibrosis News

Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapys developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced.

AD-214 is amodification of AdAltas original lead candidate for the treatment of pulmonary fibrosis (PF), AD-114. AD-214 contains two i-bodies modified antibodies that specifically target the protein CXCR4. The therapy is primarily being developed for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

Researchers at AdAlta have now completed three studies in non-human primates. One study tested a single dose of AD-214, while the two others tested multiple doses over the course of a month tested doses were 10, 30, and 100 mg/kg. The goal of these studies was to evaluate the safety of the compound and its pharmacology (the therapys effects and properties).

Results from these studies showed that AD-214 was safe and well-tolerated, with no deaths or adverse events reported. No signs of overt toxicity were seen when AD-214 was given intravenously (into the vein) at the highest dose (100 mg/kg). In addition, researchers saw no changes in body weight, nor in respiratory, cardiovascular, neurological, and ophthalmology tests.

There were, however, some reported increases in white blood cell counts immediately after treatment, but they returned to normal within a day. There were also decreases in the levels of certain blood proteins, such as albumin, which were described as slight and completely reversible.

Based on these results, the company is planning to advance the development ofAD-214 into Phase 1 trials in humans within the first few months of 2020.

Bulk manufacturing of AD-214 for Phase 1 trials was completed and done under Good Manufacturing Practice (GMP) conditions, a requirement for regulatory submissions to the U.S. Food and Drug Administration and other agencies.

We are pleased to reach both the toxicology and GMP drug substance manufacturing milestones on schedule and with expected results, enabling us to progress AD-214 into safety studies in humans as an important next step in bringing a much-needed new therapeutic option to fibrosis patients, and in demonstrating the safety of the i-body as a platform, Tim Oldham, managing director and CEO of AdAlta, said in a press release.

We also look forward to additional pharmacokinetic and pharmacodynamic information from this study in the near future, he added.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

Total Posts: 110

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Read the original post:

Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans - Pulmonary Fibrosis News